Results 51 to 60 of about 33,462 (192)

Analysis of pneumococcal vaccination status and its influencing factors among young and middle-aged populations: an online survey

Zhongguo gonggong weisheng
ObjectiveTo understand the pneumococcal vaccination status and its influencing factors among young and middle-aged populations, and provide reference for promoting pneumococcal vaccination.
Ziying CHEN, Sijia ZHOU, Xin JIANG, Wen LIU, Yuhang MA, Kai WANG, Zhixiang DAI, Shuhan TANG, Chengxi ZHENG, Jianli HU, Zhihang PENG   +10 more
doaj   +1 more source

The direct and indirect effects of the pneumococcal conjugated vaccine on carriage rates in children aged younger than 5 years in Latin America and the Caribbean: a systematic review

Einstein (São Paulo)
Objective To demonstrate the impact of pneumococcal conjugate vaccine in Streptococcus pneumoniae carriage status in children younger than 5 years in Latin America and the Caribbean. Methods A systematic literature review was carried out on the direct
Stefany Martins Silva, Izabella Caroline Gebrim Rodrigues, Rodrigo da Silva Santos, Yves Mauro Fernandes Ternes   +3 more
doaj   +2 more sources

The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia

Journal of Biomedical Science, 2020
Background Pneumococcal conjugate vaccine (PCV) reduces both invasive pneumococcal disease (IPD) and other pneumococcal infections worldwide. We investigated the impact of stepwise implementation of childhood PCV programs on the prevalence of ...
Ching-Fen Shen, Shih-Min Wang, Hsin Chi, Yi-Chuan Huang, Li-Min Huang, Yhu-Chering Huang, Hsiao-Chuan Lin, Yu-Huai Ho, Chao A. Hsiung, Ching-Chuan Liu, Taiwan Pediatric Infectious Disease Alliance   +10 more
doaj   +1 more source

Trained Immunity in Childhood Vaccination

Acta Paediatrica, EarlyView.
Trained immunity as an emerging concept in paediatric vaccinology. Trained immunity links vaccine stimuli through epigenetic and metabolic reprogramming to enhanced innate immune cell function, thereby strengthening protection against diverse pathogens while promoting adaptive immune responses through more efficient antigen presentation and co ...
ChenRongRong Cai, Lubnaa Hossenbaccus, Eva Kaufmann   +2 more
wiley   +1 more source

An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults

Human Vaccines & Immunotherapeutics
The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against vaccine-preventable disease caused by Streptococcus pneumoniae beyond the 13-valent pneumococcal conjugate vaccine (PCV13).
Kathleen McElwee, Jelena Vojicic, Charulata Sabharwal, John Ginis, Yahong Peng, Gabriel Mircus, Wendy Watson, Annaliesa Anderson   +7 more
doaj   +1 more source

Pneumococcal pneumonia and carriage in Africa before and after introduction of pneumococcal conjugate vaccines, 2000–2019: protocol for systematic review

BMJ Open, 2019
Introduction Africa harbours a high burden of pneumococcal disease, with associated high mortality rates. Despite 34 countries introducing the pneumococcal conjugate vaccine, which reduces the risk of pneumococcal carriage (a prerequisite for disease) of
Neil French, Dean Everett, Newton L. Kalata, Tinashe K. Nyazika, Todd D. Swarthout, Robert S. Heyderman, Stephen B. Gordon, Kondwani C. Jambo   +7 more
doaj   +1 more source

Would patients over 65 years of age accept vaccination while hospitalised? An assessment of eligibility and acceptability

Internal Medicine Journal, EarlyView.
Abstract Background Vaccination is effective at preventing severe illness related to influenza, pneumococcal disease and coronavirus disease 2019 COVID‐19. Vaccine coverage among older Australians is incomplete, and hospitals currently administer very few vaccine doses.
Victoria Deacon, Kristen Overton, Parthsinh Solanki, Ethan MacMinn, Anthea L. Katelaris, Jeffrey J. Post   +5 more
wiley   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

Internal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley, Philip George, Gemma Reynolds, Adam Stewart, Hang Quach, Nicole O'Leary, Zoe McQuilten, Andrea S. Henden, Lynette Chee, Chan Y. Cheah, Olivia Bupha‐Intr, Emily Blyth, Ben Teh, Monica Slavin, Michael Dickinson, Robert Weinkove   +15 more
wiley   +1 more source

Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study

The Lancet Public Health
Summary: Background: Paediatric pneumococcal conjugate vaccine (PCV) programmes in England using seven-valent PCV (PCV7) in 2006 and 13-valent PCV (PCV13) in 2010 have reduced vaccine-type invasive pneumococcal disease, but the overall effect has been ...
Yoon Hong Choi, PhD, Marta Bertran, MSc, David J Litt, PhD, Shamez N Ladhani, ProfPhD, Elizabeth Miller, ProfFMedSci   +4 more
doaj   +1 more source

Will Extended‐Valency Pneumococcal Conjugate Vaccines Offer Enhanced Coverage Against Invasive Pneumococcal Disease for At‐Risk Children?

Acta Paediatrica, EarlyView.
Robert Cohen, Corinne Levy, Naim Ouldali, Stéphane Béchet, Aude Estivaux, André Birgy, Isabelle Hau, IPD Study Group, Emmanuelle Varon   +8 more
wiley   +1 more source